Core Insights - The article highlights the launch of a new oral flea and tick treatment for dogs, FRONTPRO, by Boehringer Ingelheim at the 27th Asia Pet Expo in China [1][2] - There is a growing trend in China where pet ownership is increasing, leading to a heightened focus on pet health management among owners [2][4] Company Developments - Boehringer Ingelheim aims to enhance medication compliance with innovative products like FRONTPRO, which is designed to be palatable and easy to administer [2][4] - The company plans to continue introducing innovative solutions to meet the diverse health needs of pets throughout their lifecycle, from prevention to treatment [4] Industry Trends - The relationship between pets and their owners is evolving, with pets increasingly seen as family members, which raises the demand for better health management solutions [2] - Pet owners are willing to invest significantly in preventive care, with some spending at least 500 yuan monthly on health products for their pets [2]

据证券之星公开数据整理，近期生物股份（600201）发布2025年中报。截至本报告期末，公司营业总收 入6.2亿元，同比上升1.28%，归母净利润6042.4万元，同比下降50.84%。按单季度数据看，第二季度营 业总收入2.68亿元，同比上升1.58%，第二季度归母净利润-1605.71万元，同比下降192.65%。本报告期 生物股份三费占比上升明显，财务费用、销售费用和管理费用总和占总营收同比增幅达35.53%。 应收票据变动幅度为199.53%,原因:客户增加承兑支付。 预付款项变动幅度为355.33%,原因:预付材料款及服务费。 其他应收款变动幅度为-49.49%,原因:往来款减少。 长期股权投资变动幅度为-77.15%,原因:退出联营股权投资。 本次财报公布的各项数据指标表现一般。其中，毛利率52.24%，同比减9.8%，净利率9.47%，同比减 53.13%，销售费用、管理费用、财务费用总计1.99亿元，三费占营收比32.1%，同比增35.53%，每股净 资产4.79元，同比减0.33%，每股经营性现金流0.08元，同比减31.96%，每股收益0.06元，同比减45.45% | 项目 | 2024 ...

Group 1 - The core viewpoint of the article highlights the launch of a new oral flea and tick treatment for dogs, FRONTPRO, by Boehringer Ingelheim in China, addressing the growing demand for pet health management as pet ownership increases [1][2] - The product, FRONTPRO, is designed to be administered once a month and effectively treats multiple external parasites, including fleas, ticks, and mites, with a palatable beef-flavored chewable form [2] - The increasing importance of pets in urban households has led to a higher demand for convenient and effective pet care solutions, as traditional deworming methods often face compliance issues among pet owners [1][2] Group 2 - Boehringer Ingelheim, founded in 1885, is a major global pharmaceutical company with a diverse product portfolio that includes human pharmaceuticals, animal health, and biopharmaceutical contract manufacturing [2] - The company's recent half-year report indicates a 6.3% year-on-year increase in net sales, reaching €14 billion, with the animal health segment growing by 7.6% to €2.6 billion [2]

记者获悉，毛孩子动物保健（广东）有限公司与中瑞供应链公司联合宣布，国内首款猫用抗应激处方药 （商品名：喵内宁®）正式上市。该产品是中国农业农村部新兽药注册目录中的首款猫用加巴喷丁处方 产品，售价为69.8元（3片装）或是124.8元（6片装）。与市场中现有的喷雾、信息素、营养补剂相比， 喵内宁具有起效快、靶向程度高、安全性能更优的特点。毛孩子动保由A股上市公司健康元药业与丽珠 医药联合注资成立，成立于2023年2月。（界面） ...

证券之星消息，8月20日动物保健板块较上一交易日上涨0.27%，贤丰控股领涨。当日上证指数报收于 3766.21，上涨1.04%。深证成指报收于11926.74，上涨0.89%。动物保健板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 002141 | 后丰控股 | 4.66 | 9.91% | 128.85万 | | 5.73亿 | | 688526 | 科前生物 | 17.75 | 1.02% | 3.69万 | | 6491.03万 | | 838275 | 驱动力 | 10.24 | 0.69% | 2.68万 | | 2725.11万 | | 603566 | 普莱柯 | 15.30 | 0.39% | 5.28万 | | 8055.89万 | | 600195 | 中牧股份 | 7.70 | 0.39% | 10.24万 | | 7851.28万 | | 871970 | 大禹生物 | 10.27 | 0.39% | 3.79万 | | 3888. ...

（编辑 任世碧） 证券日报网讯 8月19日晚间，生物股份发布公告称，公司于2025年8月19日召开第十二届董事会第三次 会议，审议通过了《关于拟回购注销2023年员工持股计划部分股票的议案》，拟对公司2023年员工持股 计划离职的3名持有人尚未解锁的权益份额对应的标的股票数量2.55万股予以回购注销。 ...

Core Viewpoint - The company, Jinhe Biological, has announced the establishment of a wholly-owned subsidiary, Jinhe Aichongyi (Shanghai) Biotechnology Co., Ltd., with an investment of 10 million yuan to expand its pet business and enhance market competitiveness in the pet sector [1] Group 1 - The investment amount is 10 million yuan [1] - The new subsidiary is located in Shanghai [1] - The pet sector is a significant part of the company's strategic planning [1] Group 2 - The investment aims to further develop the company's pet business [1] - The initiative is expected to promote the development of the large animal protection industry [1]

Group 1 - The company, Jinhe Biological, announced the establishment of a wholly-owned subsidiary, Jinhe Aichongyi (Shanghai) Biotechnology Co., Ltd., with a registered capital of 10 million yuan [1] - The investment of 10 million yuan is aimed at expanding the company's pet business, which is a crucial part of its strategic planning [1] - The establishment of the subsidiary is intended to enhance the company's market competitiveness in the pet sector and promote the development of the large animal protection industry [1]

转自：证券时报 人民财讯8月19日电，生物股份(600201)8月19日晚间披露2025年半年报，公司上半年实现营业收入6.2亿 元，同比增长1.28%；归母净利润为6042.4万元，同比下降50.84%。基本每股收益0.06元。报告期内， 公司整体经营情况稳健，由于公司人用抗体药物研发费用及无形资产折旧摊销同比大幅增加，同时动保 行业竞争态势加剧，产品价格下降、毛利下滑。 ...

从资金流向上来看，当日动物保健板块主力资金净流出5474.78万元，游资资金净流入1543.37万元，散 户资金净流入3931.41万元。动物保健板块个股资金流向见下表： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。 证券之星消息，8月19日动物保健板块较上一交易日上涨3.11%，申联生物领涨。当日上证指数报收于 3727.29，下跌0.02%。深证成指报收于11821.63，下跌0.12%。动物保健板块个股涨跌见下表： ...